A Randomized Phase IIb Placebo-controlled Study of R-ICE Chemotherapy With and Without SGN-40 (Anti-CD40 Humanized Monoclonal Antibody) for Second-line Treatment of Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

This is a randomized trial to estimate the activity of R-ICE plus SGN-40 vs. R-ICE plus placebo in patients with DLBCL. The study will assess safety and tolerability and will measure any additional clinical benefit observed in patients receiving SGN-40.

Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.

Investigator(s):

Intervention(s):

  • drug : SGN-40
  • drug : placebo
  • drug : ifosfamide
  • drug : etoposide
  • drug : carboplatin
  • drug : rituximab

Phase: Phase 2

Eligibility

Ages Eligible For Study:

18 Years - 75 Years

Inclusion Criteria

- Confirmed diagnosis of de novo or transformed DLBCL, or follicular grade 3b lymphoma. - Received at least four cycles of first-line therapy with R-CHOP, or equivalent. - Best clinical response to first-line therapy of stable disease, partial response, or complete response. - At least one measureable lesion that is both greater than or equal to 1.5cm by radiographic imaging and by positive FDG-PET scan.

External Links

Explore related trials

Contact information

Primary Contact:

Sipra Choudhury 6507362563

Stanford University School of Medicine 300 Pasteur Drive Stanford, CA 94305

Stanford Medicine Resources:

Footer Links: